Women with DCIS, an early-stage form of breast cancer, can now better navigate the right treatment choices specifically for her. DCIS is slow-growing, responsive to treatment and doesn&rsquo;t spread. But women faced with a cancer diagnosis often fear for their futures, wanting aggressive treatments to ensure long life. That&rsquo;s where genomic testing comes in &ndash; changing how chemotherapy is used for invasive breast cancer and now helping identify the best treatment options. With a new test that was developed for women with DCIS, more information is also available on personal recurrence rates based on specific genetics. Armed with that knowledge, the experts can work with patients to develop even more personalized treatment options. William Farrar, MD, interim Physician-in-Chief, director, Stefanie Spielman Comprehensive Breast Center explains.